From: Deep Insights in Circular RNAs: from biogenesis to therapeutics
Neurological Disease | Circular RNA | Targets | Mechanisms | References |
---|---|---|---|---|
Inflammatory Neuropathy | hsa-circRNA 2149 | miR-138 | Specific expression in leukocytes Involved in chronic CD28 associated CD8+ T cell aging. | Fu et al., 2015 |
CircRNA hsa 2149 | ||||
Balance the expression between Th1 and Th2 through suppressing the function of RUNX3. | ||||
Alzheimer’s Disease | CDR1as | miR-7 | Downregulate AD relevant targets, such as UBE2A, which plays an important role in clearance of amyloid peptides in AD. | Zhao et al., 2016 Lukiw et al., 2016 |
Nervous system Neoplasms | CDR1-as | miR-7 | Represses the expression of EGFR, IRS1, & IRS2. Thereby reducing the active and aggressive glioblastoma. | Liu et al., 2014 |
Parkinson’s Disease | CDR1-as | miR-7 | Downregulate α-synuclein expression and protect cells against oxidative stress. | Junn et al., 2009 |
Amyotrophic lateral sclerosis | Known and Unknown CircRNAs | FUS | FUS regulates biogenesis of CircRNAs in mouse Motor Neurons. | Errichelli et al., 2017 |
Systemic lupus erythematosus | hsa: circ_102584, | (hsa-miR-766-3p, hsa-miR-762, hsa-miR-412-3p, hsa-let-7i-3p and hsa- miR-431-3p) | Mechanism not clear | Haixia et al., 2018 |
hsa: circ_400011, | (hsa-miR-296-3p, hsa-miR-146b-3p, hsa-miR-181d-3p, hsa-miR-504-3p and hsa-miR-328-5p) | |||
hsa: circ_101471 | (hsa-miR-136-5p, hsa-miR-665, hsa-miR-486-3p, hsa-miR-601 and hsa-miR-30b-3p) | |||
hsa: circ_100226 | (hsa-miR-138-5p, hsa-miR-145-3p, hsa-miR-24-3p, hsa-miR-620 and hsa-miR-875-3p) |